Health · Pharma & Biotech · 1 hr ago
ABL Bio to present data on two cancer drug candidates at ESMO
ABL Bio will present clinical data on two drug candidates at the European Society for Medical Oncology meeting.
The company is based in South Korea, and the meeting will take place in Madrid, Spain, from October 23 to 27.
The candidates are givastomig and ragistomig, also known as ABL111 and ABL503.
Both are bispecific immuno-oncology drug candidates, a type of cancer treatment being studied in clinical trials.
ABL Bio plans to share the data in poster presentations at ESMO.
The presentations will make clinical findings on both candidates available to people attending the meeting.
ABL Bio plans to present clinical data on two dual-antibody immuno-oncology candidates at the European Society for Medical Oncology congress.
The candidates are givastomig, also known as ABL111, and ragistomig, also known as ABL503.
The data will be presented as posters.
The congress is scheduled to take place in Madrid from October 23 to 27, local time.
ABL Bio announced the plan on October 19.
- Who
- ABL Bio.
- What
- It plans to present clinical data on two dual-antibody drug candidates.
- When
- October 23–27, local time.
- Where
- The ESMO congress in Madrid, Spain.
- Why
- Not stated.
This story does not have two clearly opposing sides.
ABL Bio announced that it would present clinical data on two candidates at ESMO.
ESMO is scheduled to take place in Madrid, where ABL Bio plans to present the data as posters.
- Company
- ABL Bio
- Candidate 1
- Givastomig (ABL111)
- Candidate 2
- Ragistomig (ABL503)
- Presentation format
- Posters
- Congress location
- Madrid, Spain
- Congress dates
- October 23–27, local time